No Data
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
B. Riley Downgrades Actinium Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $16
IONETIX Closes Financing Led by Tees River and Eli Lilly and Company
Express News | Actinium Pharmaceuticals Inc : Stephens Cuts Target Price to $5 From $25
Actinium Pharmaceuticals Price Target Cut to $4.00/Share From $50.00 by HC Wainwright & Co.
Actinium Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
lpfc1926 : 8 $